Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersMedical Oncology Physician in Boston, MA
NPI: 1275734527Primary Practice Location
BETH ISRAEL DEACONESS HOSPITAL - NEEDHAM
148 Chestnut St, Needham, MA
Primary Employer
Harvard Medical Faculty Phys at Beth Israel Deaconess
hmfphysicians.org
HQ Phone
Get M.D. Deepa's Phone Numberphone_androidMobile
Get M.D. Deepa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMD State Medical License
MA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 56 | 212 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 31 | 45 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 30 | 99 |
| 4 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 17 | 19 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 11 | 12 |
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Authors: Paul Vanderlaan, Daniel Costa, Brian Carney
Publication Date: 2017-08
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Authors: Jennifer Faig, Sarah Hammond, Matthew Cheng, Francisco Marty, Mark Huberman, Daniel Costa
Publication Date: 2017-12-19
Authors: Mark Kris, Joel Neal, Zofia Piotrowska, Jamie Chaft, Mark Huberman, Lecia Sequist, Michael Lanuti, James Huang, Daniel Costa, Joseph Shrager
Journal: JCO Precis Oncol
Publication Date: 2021-02-01
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: DRUG: Ipilimumab, DRUG: Nivolumab
Lead Sponsor: Zofia Piotrowska
Collaborators: AstraZeneca
Intervention / Treatment: DRUG: Temozolomide, DRUG: Olaparib
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: Rovalpituzumab tesirine
